Chronic Inflammation Induced Immunosuppression in Tumor Microenvironment of Oral Cancer
Keywords:
myeloid derived suppressor cells, chronic inflammation, oral cancer, granulocytic monocytic colony stimulating factor, natural killer cells, transform
Abstract
Oral Cancer is a wound that do not heal is a complex disease consists of heterogeneous tissue in their tumor microenvironment. Oral cancer accounts eighth most Common Cancer worldwide. Chronic inflammatory mediators released from immune cells in tumor microenvironment of oral cancer such as macrophages, T lymphocytes, dendritic cells ,Natural killer cells release cytokines, Chemokine's and growth factors helps in generation of myeloid derived suppressor cells. Myeloid derived suppressor cells are derived from myeloid progenitor cells of bone marrow secretes inflammatory mediators iNOS, arginase-1, PGE2,IL-10 and IL-4 suppresses adaptive and innate immunity by interacting with macrophages ,T-cells, Natural killer cells and dendritic cells favours pro-tumoral activity by activating transcriptional factors (NF-KB,STAT -3,HIF) further progress in to oral cancer. Myeloid derived suppressor cells reduces T cell activation and function by Arginase-1, iNOS, peroxynitrate over expression and cysteine depletion. This article describes mainly about immune cells in tumor microenvironment especially macrophages, T lymphocytes, dendritic cells, Natural killer cells their interactions with myeloid derived suppressor cells.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
A. Pietras k, Ostman (2010) Hallmarks of cancer; Interactions with the tumorstroma. 316, 1324-1331.
Thomas Condamine, Indu Ramachandran, Je-In Youn, Dmitry Gabrilovich (2015) Regulation of tumor metastasis by myeloid-derived suppressor cells.Annual review of medicine. 66(1), 97-110. https://doi.org/10.1146/annurev-med-051013-052304
Elisa Peranzoni, Serena Zilio, Ilaria Marigo, Luigi Dolcetti, Paola Zanovello, Susanna Mandruzzato, Vincenzo Bronte (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. 22(2), 238-244. https://doi.org/10.1016/j.coi.2010.01.021
F. Colotta, P. Allavena, A. Sica, C. Garlanda, A. Mantovani (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. 30(7), 1073-1081. https://doi.org/10.1093/carcin/bgp127
Fiaschi T, Chiarugi P (2012) Oxidative Stress, Tumor Microenvironment, and Metabolic Reprogramming: A Diabolic Liaison. 2012, 80-88.
Bauer H, Jung T, Tsikas D, Stichtenoth DO, Frolich JC, Neumann C (1997) Nitric oxide inhibits the secretion of T‐helper 1‐ and T‐helper 2‐associated cytokines in activated human T cells'pa. 90(2), 205-211. https://doi.org/10.1046/j.1365-2567.1997.00161.x
W. Sosroseno, P. Bird, G. Seymour (2009) Effect of exogenous nitric oxide on murine splenic immune response induced by Aggregatibacter actinomycetemcomitans lipopolysaccharide. 15(3), 95-98. https://doi.org/10.1016/j.anaerobe.2009.01.002
Roland Bingisser, Peta Tilbrook, Patrick Holt, Ursula Kees (1998) Macrophage-Derived Nitric Oxide Regulates T Cell Activation via Reversible Disruption of the Jak3/STAT5 Signaling Pathway. 160(12), 5729-5734. https://doi.org/10.4049/jimmunol.160.12.5729
Laura Edgington-Mitchell, Belinda S (2014) Parker Disparate functions of myeloid-derived suppressor cells in cancer metastasis. 38, 38-77.
P. Lejeune, P. Lagadec, N. Onier, D. Pinard, H. Ohshima, J. Jeannin (1994) Nitric oxide involvement in tumor-induced immunosuppression. 152(10), 5077-5083. https://doi.org/10.4049/jimmunol.152.10.5077
Alessandra Mazzoni, Vincenzo Bronte, Alberto Visintin, Jessica Spitzer, Elisa Apolloni, Paolo Serafini, Paola Zanovello, David Segal (2002) Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism. 168(2), 689-695. https://doi.org/10.4049/jimmunol.168.2.689
Marianne Medot-Pirenne, Michelle Heilman, Malinee Saxena, Patricia McDermott, Charles Mills (1999) Augmentation of an Antitumor CTL Response In Vivo by Inhibition of Suppressor Macrophage Nitric Oxide. 163(11), 5877-5882. https://doi.org/10.4049/jimmunol.163.11.5877
Kazuya Sato, Katsutoshi Ozaki, Iekuni Oh, Akiko Meguro, Keiko Hatanaka, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. 109(1), 228-234. https://doi.org/10.1182/blood-2006-02-002246
Olivier Harari, James Liao (2004) Inhibition of MHC II Gene Transcription by Nitric Oxide and Antioxidants. 10(8), 893-898. https://doi.org/10.2174/1381612043452893
Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. 188(1), 97-113. https://doi.org/10.1034/j.1600-065x.2002.18809.x
Christian Bogdan (2001) Nitric oxide and the immune response. 2(10), 907-916. https://doi.org/10.1038/ni1001-907
S. Morris, Jr (2002) Regulation of enzymes of the urea cycle and arginine metabolism. 22, 87-105.
Zhao W, Xu Y, Xu J, Wu D, Zhao B, Yin Z, Wang X (2015) Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially International immunopharmacology. 26(2), 314-321.
Serafini Bronte V, Marigo De Santo C, Mazzoni Tosello V, et a (2003) IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice. 170(1), 270-278. https://doi.org/10.4049/jimmunol.170.1.270
José Medina-Echeverz, Fernando Aranda, Pedro Berraondo (2014) Myeloid-derived cells are key targets of tumor immunotherapy Oncoimmunology. 3(4), e28398.
Rodriguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. 222(1), 180-191. https://doi.org/10.1111/j.1600-065x.2008.00608.x
K. Parker, D. Beury, S. Ostrand-Rosenberg (2015) Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment Advances in Cancer Research. 12, 25-32.
Srinivas Nagaraj, Kapil Gupta, Vladimir Pisarev, Leo Kinarsky, Simon Sherman, Loveleen Kang, Donna Herber, Jonathan Schneck, Dmitry Gabrilovich (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. 13(7), 828-835. https://doi.org/10.1038/nm1609
Jiang J, Guo W, Liang X (2014) Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients Human immunology. 75(11), 1128-1137.
Minu Srivastava, Pratima Sinha, Virginia Clements, Paulo Rodriguez, Suzanne Ostrand-Rosenberg (2010) Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. 70(1), 68-77. https://doi.org/10.1158/0008-5472.can-09-2587
Keskinov AA, Shurin MR (2015) Myeloid regulatory cells in tumor spreading and metastasis Immunobiology. 220(2), 236-242.
Evgeniy Eruslanov, Irina Daurkin, Javier Ortiz, Johannes Vieweg, Sergei Kusmartsev (2010) Pivotal advance; Tumor -mediated induction of myeloid -derived suppressor cells and M2- polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells J Leukol. 88(5), 839-848. https://doi.org/10.1189/jlb.1209821
Legler DF, Bruckner M, Vetz-Von E, Krause P (2010) Prostaglandin E2 at new glance; Novel insights in functional diversity offer therapeutic chances International. 42(2), 198-201. https://doi.org/10.1016/j.biocel.2009.09.015
Suzanne Ostrand-Rosenberg, Pratima Sinha, Daniel Beury, Virginia Clements (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. 22(4), 275-281. https://doi.org/10.1016/j.semcancer.2012.01.011
Dilek N, Vuillefroy R, Blancho G, Vanhove B (2012) Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. 3, 208-218. https://doi.org/10.3389/fimmu.2012.00208
E. LO Manaco, E. Tremante, C. Cerboni, E. Melluci, L. Sibilio, A. Zingoni (2011) Human Leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. 13, 822-830.
Harda A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. 56(5), 559-564. https://doi.org/10.1002/jlb.56.5.559
Xu Q, Wang L, Li H (2012) Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial -mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta. 41, 46-58.
H. Wang, J. Wu, Y. Zhang Transforming growth factor beta - induced epithelial -mesenchymal transition.
Elia AR, Cappello P, Puppo M (2010) Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. 84, 165-171.
Yang M, Ma C, Liu S (2010) HIF‐dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2‐stimulating phenotype under hypoxia. 88(2), 165-171. https://doi.org/10.1038/icb.2009.77
M. Douglas, I. Dmitry, Gabrilovich (2015) Gabrilovich Myeloid derived suppressor cells in the tumor microenvironment; Expect the unexpected. 7, 1125-1135.
I. Poschke, Y. Mao, L. Adamson, F. Salazar-Onfray, G. Masucci, R. Kiessling Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. 8, 210-213.
Brent McKenzie, Robert Kastelein, Daniel Cua (2006) Understanding the IL-23-IL-17 immune pathway. 27(1), 17-23. https://doi.org/10.1016/j.it.2005.10.003
(2014) Myeloid-Derived Suppressor Cells and Tumor Growth. 91-109.
C. Diaz-Montero, Jim Finke, Alberto Montero (2014) Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications. 41(2), 174-184. https://doi.org/10.1053/j.seminoncol.2014.02.003
Teng MW, Andrews DM, McLaughlin N, von B, Ngiow SF, Moller A (2010) IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. 107(18), 8328-8333. https://doi.org/10.1073/pnas.1003251107
W. Sosroseno (2009) Effect of exogenous nitric oxide on murine splenic immune response induced by Aggregatibacter actinomycetemcomitans lipopolysaccharide. 15(3), 95-98. https://doi.org/10.1016/j.anaerobe.2009.01.002
R. Bingisser (1998) Macrophage-Derived Nitric Oxide Regulates T Cell Activation via Reversible Disruption of the Jak3/STAT5 Signaling Pathway. 160(12), 5729-5734. https://doi.org/10.4049/jimmunol.160.12.5729
P. Bobe (1999) Nitric Oxide Mediation of Active Immunosuppression Associated With Graft-Versus-Host Reaction. 94, 1028-1037.
P. Lejeune (1994) Nitric oxide involvement in tumor-induced immunosuppression. 152(10), 5077-5083. https://doi.org/10.4049/jimmunol.152.10.5077
A. Mazzoni (2002) Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism. 168(2), 689-695. https://doi.org/10.4049/jimmunol.168.2.689
M. Medot-Pirenne (1999) Augmentation of an Antitumor CTL Response In Vivo by Inhibition of Suppressor Macrophage Nitric Oxide. 163(11), 5877-5882. https://doi.org/10.4049/jimmunol.163.11.5877
K. Sato (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. 109(1), 228-234. https://doi.org/10.1182/blood-2006-02-002246
O. Harari (2012) Inhibition of MHC II Gene Transcription by Nitric Oxide and Antioxidants. 10(8), 893-898. https://doi.org/10.2174/1381612043452893
L. Rivoltini (2013) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. 188(1), 97-113. https://doi.org/10.1034/j.1600-065x.2002.18809.x
Christian Bogdan (2011) Nitric oxide and the immune response. 2(10), 907-916. https://doi.org/10.1038/ni1001-907
S. Morris (2002) Regulation of enzymes of the urea cycle and arginine metabolism. 22, 87-105.
G. Wu (1998) Arginine metabolism: nitric oxide and beyond. 336(1), 1-17. https://doi.org/10.1042/bj3360001
V. Bronte (2003) IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice. 170(1), 270-278. https://doi.org/10.4049/jimmunol.170.1.270
V. Bronte (2005) Regulation of immune responses by L-arginine metabolism. 5(8), 641-654. https://doi.org/10.1038/nri1668
P. Rodriguez (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. 222, 180-191.
P. Rodriguez (2004) Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. 64(16), 5839-5849. https://doi.org/10.1158/0008-5472.can-04-0465
S. Nagaraj (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. 13(7), 828-835. https://doi.org/10.1038/nm1609
P. Gout (2011) Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc − cystine transporter: a new action for an old drug. 15(10), 1633-1640. https://doi.org/10.1038/sj.leu.2402238
M. Srivastava (2010) Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. 70(1), 68-77. https://doi.org/10.1158/0008-5472.can-09-2587
S. Ostrand -Rosenberg (2009) Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. 188, 4499-4506.
E. Eruslanov (2010) Pivotal advance ; Tumor - mediated induction of myeloid -derived suppressor cells and M2- polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J. Leukol. 88(5), 839-848. https://doi.org/10.1189/jlb.1209821
D. Legler (2010) Prostaglandin E2 at new glance; Novel insights in functional diversity offer therapeutic chances. International. 42(2), 198-201. https://doi.org/10.1016/j.biocel.2009.09.015
S. Ostrand -Rosenberg (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. 22, 275-281.
N. Dilek (2014) Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. 3, 208-214.
E. LO Manaco (2011) Human Leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. 13, 822-830.
A. Harda (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. 56, 559-564.
Q. Xu (2012) Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial -mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta. 41, 46-58.
H. Wang (2012) Transforming growth factor β-induced epithelial-mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line. 3(1), 229-233. https://doi.org/10.3892/ol.2011.448
Q. Jiang (2000) Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of NF-κB. 165(7), 3541-3544. https://doi.org/10.4049/jimmunol.165.7.3541
Y. Wang (2012) Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. 59(2), 228-236. https://doi.org/10.1016/j.cyto.2012.04.020
E. Tindall (2012) Interleukin‐6 promoter variants, prostate cancer risk, and survival. 72(16), 1701-1707. https://doi.org/10.1002/pros.22557
A. Mancino (2008) Divergent effects of hypoxia on dendritic cell functions. 112(9), 3723-3734. https://doi.org/10.1182/blood-2008-02-142091
A. Elia (2010) Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. 84, 165-171.
M. Yang (2010) HIF‐dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2‐stimulating phenotype under hypoxia. 88(2), 165-171. https://doi.org/10.1038/icb.2009.77
Dmitry Gabrilovich (2014) Mechanisms and functional significance of tumour-induced dendritic-cell defects. 4(12), 941-952. https://doi.org/10.1038/nri1498
I. Poschke (2011) Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. 8, 210-213.
B. McKenzie (2006) Understanding the IL-23-IL-17 immune pathway. 27(1), 17-23. https://doi.org/10.1016/j.it.2005.10.003
C. Langrish (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. 201, 233-240.
J. Langowski (2006) IL-23 promotes tumour incidence and growth. 442(7101), 461-465. https://doi.org/10.1038/nature04808
M. Teng (2010) IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. 107(18), 8328-8333. https://doi.org/10.1073/pnas.1003251107
D. Mittal (2014) New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape. 27, 16-25. https://doi.org/10.1016/j.coi.2014.01.004
Published
2016-08-08
Issue
Section
License
Copyright (c) 2016 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.